Dr Terri Cooper is a member of the Investment Committee and the Nominations Committee. Terri is a recognised life sciences healthcare expert, with more than 35 years’ experience working globally across public and private sectors with complex industry, business, technology, DEI, brand-building and regulatory imperatives. This includes leading Deloitte’s global healthcare sector and building the firm’s Life Sciences R&D practice. Terri is the board chair for Verso Biosense, the vice board chair for the Classical Theatre of Harlem and sits on the advisory boards of the USTA Foundation and EnrichedHQ. She holds a PhD in pharmacology from the University of London.
Dr Terri Cooper
Latest news
-
LifeArc welcomes the UK government’s national action plan for antimicrobial resistance (AMR)
Read more: LifeArc welcomes the UK government’s national action plan for antimicrobial resistance (AMR) -
LifeArc Translational Science Summit: Highlights and key takeaways
Read more: LifeArc Translational Science Summit: Highlights and key takeaways -
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases